Becton, Dickinson and Company (BDX)
Healthcare · Medical - Instruments & Supplies · Data as of 2026-10-22
Bottom line
BDX is trading at a premium to its history, near its historical resistance zone, and recent volume shows no clear direction. Historically, this combination has called for extra caution. Past patterns are not a guarantee of future results.
Valuation — Trading at a premium (Red)
BDX trades at 58× earnings, above its own 5-year average of 31× and above similar healthcare companies we track (28×, 53 peers). Investors are currently paying more per dollar of earnings than usual. Its free-cash-flow yield is about 5.0%. Growth is slower than its 3-year pace, which deserves some caution. Its current multiple sits around the 98th percentile of its own last five years — near the top of its own range.
Price zones — Near its historical resistance zone (Red)
At $200.42, the stock is close to the upper end of its recent range. Over the past year BDX has traded between $127.59 and $200.47; its historical support zone sits near $185.03 and resistance near $200.47. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $127.59–$200.47 · 50-day average $185.03 · 200-day average $164.88
Money flow — No clear direction (Yellow)
Buying and selling volume in BDX have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 0.8× volume on down days over the last 30 sessions.
Dividends & company facts
BDX paid $3.98 a share in dividends over the past year — 2.0% of today's price — and has raised it in each of the last five years. It also bought back shares: $1.0 billion in fiscal 2025, about 1.9% of its market value.
- Dividend yield (12 months)
- 1.98%
- Paid over 12 months
- $3.98 a share
- Payout ratio
- 187.1%
- Buybacks
- 1.91% (fiscal 2025)
- Shares, past year
- -4.7%
- Revenue, 12 months
- $20.8B
- Profit, 12 months
- $941M
- Employees
- 72,000
- CEO
- Thomas E. Polen Jr.
- Headquarters
- Franklin Lakes, NJ
- Listed since
- 1973 · NYSE
About the company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world.
Related stocks
一句话结论
BDX 相对自身历史处于溢价水平，接近其历史阻力区，近期成交量没有明确方向。从历史来看，这样的组合需要格外谨慎。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于溢价水平
BDX 目前的市盈率为 58×，高于其自身 5 年平均的 31×，并且高于我们追踪的同类Healthcare公司（28×，53 家）。投资者目前为每一美元盈利付出的价格高于以往。其自由现金流收益率约为 5.0%。增速已慢于其 3 年的平均步伐，这一点值得留意。它当前的估值倍数大约位于自身过去五年分布的第 98 百分位——接近自身区间的顶部。
价格区间 — 接近其历史阻力区
目前价格为 $200.42，接近其近期区间的上沿。过去一年 BDX 的价格在 $127.59 到 $200.47 之间波动；其历史支撑区在 $185.03 附近，阻力区在 $200.47 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 方向不明确
BDX 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 0.8×。
股息与公司概况
BDX 过去一年每股派息 3.98 美元，相当于当前股价的 2.0%，过去五年每年都有上调。它也回购了股票：2025 财年回购 10.0亿美元，约占市值的 1.9%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.